Latest Breaking News On - John laterra - Page 1 : comparemela.com

Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights

DALLAS (BUSINESS WIRE) Nov 8, 2023

South koreaBritish columbiaUnited statesKishor bhatiaJohn laterraJohns hopkins medicine kennedy krieger instituteLantern pharma incSociety for neuroFox chase cancer centerSecurities exchangeExchange commission onAi machine learning to accelerate the developmentStarlight therapeutics incPanna sharmaPowered pipelineJohns hopkins

Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month

/PRNewswire/ Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and.

United statesMatthias holdhoffMattias holdhoffJohn laterraKishor bhatiaFreie universitJohns hopkinsNicole leberDivision of neuroJohns hopkins bayview medical centerBrain cancer programExchange commission onUniversity of michigan at ann arborUniversity medicine berlinJohns hopkins university school of medicineOncology at johns hopkins school of medicine

Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration

Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesDavid waldmanJohn laterraNicholas koulermosJohns hopkinsJohns hopkins universityExchange commission onCrescendo communicationsSecurities exchangeKennedy krieger instituteLantern pharmaAbout lanternSecurities actSecurities exchange actRisk factorsAnnual report

Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration

Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma

Share this article Share this article DALLAS, Dec. 17, 2020 /PRNewswire/ Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR ® artificial intelligence ( A.I. ) platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced a collaboration and research agreement with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Kennedy Krieger Institute. The collaboration will focus on the further development of Lantern s LP-184 in glioblastoma multiforme (GBM). Based in Baltimore, Johns Hopkins is a leading research center for brain cancers and one of the largest brain tumor treatment and research centers in the world with a focus on treating an extremely large number of patients affected by all types of brain tumors.

United statesMarek ciszewskiJohn laterraKishor bhatiaJohns hopkinsDivision of neuroNational cancer instituteBrain cancer programDrug administrationJohns hopkins sidney kimmel comprehensive cancer centerExchange commissionOncology at johns hopkins school of medicineLantern pharma incSecurities exchangeKennedy krieger instituteLantern pharma